Editing policy to fit the genome?
Authors:
- 22 January 2016
- journal article
- policy forum
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 351 (6271) , 337-339
Abstract
Balancing therapeutic prospects brought by scientific advances with regulation to address highly contested socioethical issues is the ultimate challenge in dealing with disruptive science. Human genome editing is a powerful tool that offers great scientific and therapeutic potential (1, 2). Yet, it rejuvenates socioethical and policy questions surrounding the acceptability of germline modification.Keywords
Funding Information
- EUCelLEX EU-FP7 Program (601806)
- Canada Research Chair
This publication has 11 references indexed in Scilit:
- No time to waste—the ethical challenges created by CRISPREMBO Reports, 2015
- Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9International Journal of Pharmaceutics, 2015
- UK scientists apply for licence to edit genes in human embryosNature, 2015
- Ethics and germline gene editingEMBO Reports, 2015
- A prudent path forward for genomic engineering and germline gene modificationScience, 2015
- Don’t edit the human germ lineNature, 2015
- The new frontier of genome engineering with CRISPR-Cas9Science, 2014
- Beyond the permissibility of embryonic and stem cell research: substantive requirements and procedural safeguardsHuman Reproduction, 2006
- Mind the Gap: Policy Approaches to Embryonic Stem Cell and Cloning Research in 50 CountriesEuropean Journal of Health Law, 2006
- Regulatory approaches to reproductive genetic testingHuman Reproduction, 2004